Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

60760258

A replay of the webcast will be available through May 17, 2007 and may be accessed by dialing 1-888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 25344900. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.

Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures.

Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Dyax is headquartered in Cambridge, Massachusett
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

Post Your Comments:
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...www.reportlinker.com/p0164220/Pain-Management---Gl... generic drugs, emergence of pain management clini...he pace of growth in the pain management market. H...
(Date:11/25/2009)..., , DELFT, The Netherlands and JOHA...maceuticals, service division and Pyxis Discovery ...ive agreement to jointly market both,companies, se...al chemistry and lead discovery expertise,will be ... medicinal and,synthetic chemistry support to proj...
(Date:11/25/2009)..., , MOUNTAIN VIEW, Calif., Nov. 25 /PRNewsw... Phase II/III clinical data from the Company,s PRO...aluation in Crohn,s disease Trial) of Traficet-EN(... Crohn,s disease demonstrated clinical efficacy wi...he study demonstrated evidence of clinical efficac...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Elseviers PharmaPendium introduces the FDA Classic Collection 47610 1Elseviers PharmaPendium introduces the FDA Classic Collection 47610 2SRI International announces findings from new upper atmospheric radar system for scientific research 8688 1SRI International announces findings from new upper atmospheric radar system for scientific research 8688 2SRI International announces findings from new upper atmospheric radar system for scientific research 8688 3SRI International announces findings from new upper atmospheric radar system for scientific research 8688 4National Partnership to Meet Evaluate Addiction Treatment as Component of New Justice Programs 47608 1National Partnership to Meet Evaluate Addiction Treatment as Component of New Justice Programs 47608 2National Partnership to Meet Evaluate Addiction Treatment as Component of New Justice Programs 47608 3
...MP4 and BMP7 inhibit the,growth of medulloblastoma...,into normal neurons, a finding that may lead to b...March 14 A discovery by St.,Jude Children,s Resea...eat,medulloblastoma, a rare but often fatal childh...rain,s signaling pathways inhibits the growth of t...
...maceuticals,Inc. today announced that enrollment h...ts that evaluates the safety and efficacy of its l...umatoid arthritis (RA). MM-093 is a,recombinant ve...omized, double-blind, placebo-controlled, Phase 2 ...the United States. The objective,of this study is ...
Other Medicine Technology:St. Jude Finds Signaling System That Halts the Growth of a Childhood Brain Cancer 2Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis 2
(Date:11/27/2009)...dings has announced that it has become a national ...rgest nonprofit organizations dedicated to arthrit... Delray Beach, FL (Vocus) Novembe...), a company specializing in the marketing and ret...has announced today that is has become a national ...
(Date:11/27/2009)...edical, economic burdens, study predicts , ...r of people with diabetes in the United States is ...tudy predicts. , That would bring the total by ..., up from 23.7 million today. , , At the same ti... triple, the study also warns, rising from an esti...
(Date:11/27/2009)...h™ announced today that Spectrum Health (Gra...terprise orthopedic templating solution and its Tr... (PRWEB) November 27, 2009 -- Voyant Hea...rand Rapids, Michigan) has licensed its TraumaCad ...TraumaCad Extend workflow solution, to allow its o...
(Date:11/27/2009)...anufacturers who use medical load cells at the hea...s by bringing in technology partner Flintec early ...ctive medical manufacturers are calling in Flintec...rojects, ensuring that progress will not be constr...outdated technology. , (P...
(Date:11/26/2009)...ire/ -- With cold and flu season upon us, it,s mor...control the spread of infections and avoid illness...ourselves healthy, but to avoid transmitting illne...C (certified in infection-control), nursing direct...t Hospital for Special Surgery (HSS) in Manhattan....
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
... BRUSSELS and LA GAUDE, France, May 13 IBM (NYSE:...lobal Healthcare Centre of Excellence located in L...com.com/cgi-bin/prnh/20090416/IBMLOGO ) , , Ex...utions that improve care delivery, predict and pre...
... Surgeon receives top score in Carolinas Medical C...13 Dr. Peter J. Capizzi of Stillwater Plastic Sur...he 2008 Carolinas Medical Center-University patien...es the program and selects the honorees. "The pati...
...n U.S., 40 percent of new moms aren,t married, CDC...ay News) -- The number of unmarried women having c... several other countries, according to U.S. health...ng to a report, Changing Patterns of Nonmarital C...
... HOUSTON (May 13, 2009) The beta-carotene in so...ans, according to researchers at Baylor College of... article that appears in the current issue of the ... of creating rice that had beta-carotene -- a vita...
... CEP America,s Longest-Standing Client Congratulat...ious Designation , , EMERYVILLE, Calif., May 13...rs of emergency department (ED) management and sta...entialing Center (ANCC). Only five percent of U.S....
... Voters willing to engage in discussion about trad...nt answers to tough questions about the trade-offs...data released today by the Stanford Center on Long...ds of politics, academia and the public. , , "As ...
Other Medicine News:Health News:IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France 2Health News:IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France 3Health News:Dr. Peter J. Capizzi of Stillwater Plastic Surgery Honored in Patient Satisfaction Survey 2Health News:More Single Women Are Having Babies 2Health News:More Single Women Are Having Babies 3Health News:More Single Women Are Having Babies 4Health News:Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center 2Health News:Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center 3Health News:Stanford Center on Longevity Releases New Findings About Voter Attitudes on Health Care Reform 2
Clinical Xpert™ PDA Medical Reference and Decision-Support Tool
Diagnosoft HARP Cardiac MRI Tagging
VISULAS YAG III Combi Complete Laser Therapy System
...olter Monitoring System, equipped with the latest ...lysis algorithm, Heart Rate Variability analysis a...s with an Epicardia System in place have complete ...suit their needs, and managing their data. The Epi...
Medicine Products: